Anika Therapeutics (ANIK) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 09, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	Anika Therapeutics, Inc.
Entity Central Index Key	898,437
Trading Symbol	anik
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		14,693,928
Entity Public Float			$ 702,114,713
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 133,256	$ 104,261
Investments	24,000	20,500
Accounts receivable, net of reserves of $1,914 and $194 at December 31, 2017 and December 31, 2016, respectively	23,825	27,598
Inventories, net	22,035	15,983
Prepaid expenses and other current assets	3,211	2,098
Total current assets	206,327	170,440
Property and equipment, net	56,183	52,296
Other long-term assets	1,254	69
Intangible assets, net	10,635	10,227
Goodwill	8,218	7,214
Total assets	282,617	240,246
Current liabilities:
Accounts payable	6,747	2,303
Accrued expenses and other current liabilities	6,326	6,496
Total current liabilities	13,073	8,799
Other long-term liabilities	660	2,126
Deferred tax liability	5,393	6,548
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively	0	0
Common stock, $0.01 par value; 60,000 shares authorized, 14,688 and 14,627 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively	147	146
Additional paid-in-capital	68,617	61,735
Accumulated other comprehensive loss	(4,784)	(7,317)
Retained earnings	199,511	168,209
Total stockholders’ equity	263,491	222,773
Total liabilities and stockholders’ equity	$ 282,617	$ 240,246

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, reserves	$ 1,914	$ 194
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,250	1,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000	60,000
Common stock, shares issued (in shares)	14,688	14,627
Common stock, shares outstanding (in shares)	14,688	14,627

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Product Revenue	$ 107,783	$ 102,932	$ 87,696
Licensing, milestone and contract revenue	5,637	447	5,303
Total revenue	113,420	103,379	92,999
Operating expenses:
Cost of product revenue	27,364	24,027	21,053
Research & development	18,787	10,732	8,987
Selling, general & administrative	21,540	18,013	14,825
Total operating expenses	67,691	52,772	44,865
Income from operations	45,729	50,607	48,134
Interest income, net	473	263	120
Income before income taxes	46,202	50,870	48,254
Provision for income taxes	14,386	18,323	17,496
Net income	$ 31,816	$ 32,547	$ 30,758
Basic net income per share:
Net income (in dollars per share)	$ 2.18	$ 2.22	$ 2.06
Basic weighted average common shares outstanding (in shares)	14,575	14,682	14,934
Diluted net income per share:
Net income (in dollars per share)	$ 2.11	$ 2.15	$ 2.01
Diluted weighted average common shares outstanding (in shares)	15,068	15,116	15,321
Net income	$ 31,816	$ 32,547	$ 30,758
Foreign currency translation adjustment	2,533	(668)	(2,154)
Comprehensive income	$ 34,349	$ 31,879	$ 28,604

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2014	14,852
Balance at Dec. 31, 2014	$ 149	$ 77,540	$ 104,904	$ (4,495)	$ 178,098
Issuance of common stock for equity awards (in shares)	185
Issuance of common stock for equity awards	$ 1	1,073			1,074
Tax benefit related to equity awards		847			847
Stock-based compensation expense		2,225			2,225
Net income			30,758		30,758
Other comprehensive loss				(2,154)	(2,154)
Balance (in shares) at Dec. 31, 2015	15,037
Balance at Dec. 31, 2015	$ 150	81,685	135,662	(6,649)	210,848
Issuance of common stock for equity awards (in shares)	121
Issuance of common stock for equity awards	$ 1	1,006			1,007
Tax benefit related to equity awards		647			647
Stock-based compensation expense		3,392			3,392
Net income			32,547		32,547
Other comprehensive loss				(668)	(668)
Repurchase of common stock (in shares)	(531)
Repurchase of common stock	$ (5)	(24,995)			(25,000)
Balance (in shares) at Dec. 31, 2016	14,627
Balance at Dec. 31, 2016	$ 146	61,735	168,209	(7,317)	222,773
Issuance of common stock for equity awards (in shares)	61
Issuance of common stock for equity awards	$ 1	313			314
Stock-based compensation expense		5,807			5,807
Net income			31,816		31,816
Other comprehensive loss				2,533	2,533
Balance (in shares) at Dec. 31, 2017	14,688
Balance at Dec. 31, 2017	$ 147	68,617	199,511	(4,784)	263,491
Cumulative effect of change in accounting for stock-based compensation		$ 762	$ (514)		$ 248

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ 31,816	$ 32,547	$ 30,758
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,290	3,734	3,775
Loss on disposal of fixed assets	150
Stock-based compensation expense	5,807	3,392	2,225
Deferred income taxes	(1,198)	(65)	(747)
Provision for doubtful accounts	1,609	52	38
Provision for inventory	695	654	210
Non-cash impairment charges for IPR&D			697
Changes in operating assets and liabilities:
Accounts receivable	2,674	(6,201)	(4,996)
Inventories	(6,521)	(1,738)	(2,939)
Prepaid expenses, other current and long-term assets	(1,454)	(898)	89
Accounts payable	3,890	(5,059)	5,625
Accrued expenses and other current liabilities	(605)	1,566	(199)
Income taxes payable	367	(3,552)	5,484
Other long-term liabilities	(708)	16	(109)
Net cash provided by operating activities	40,812	24,448	39,911
Cash flows from investing activities:
Proceeds from maturity of investments	41,500	46,500	24,250
Purchase of investments	(45,000)	(39,249)	(45,251)
Purchase of property and equipment, net	(8,980)	(14,014)	(9,225)
Net cash used in investing activities	(12,480)	(6,763)	(30,226)
Cash flows from financing activities:
Repurchase of common stock		(25,000)
Proceeds from exercise of equity awards	314	1,007	1,074
Net cash (used in) provided by financing activities	314	(23,993)	1,074
Exchange rate impact on cash	349	(138)	(208)
Increase (Decrease) in cash and cash equivalents	28,995	(6,446)	10,551
Cash and cash equivalents at beginning of period	104,261	110,707	100,156
Cash and cash equivalents at end of period	133,256	104,261	110,707
Supplemental disclosure of cash flow information:
Cash paid for income taxes	15,088	22,826	12,724
Non-cash Investing Activities:
Purchases of property and equipment included in accounts payable and accrued expenses	1,891	1,257	1,949
Build-to-suit lease agreement	$ 0	$ 1,723	$ 30

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	1. Anika Therapeutics, Inc. (the “Company”) is a global, integrated orthopedic medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. All intercompany balances and transactions have been eliminated in consolidation. Foreign Currency Translation The functional currency of the Company’s foreign subsidiary is the Euro. Assets and liabilities of the foreign subsidiary are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive loss which resulted in a gain (loss) from foreign currency translation of $2.5 $0.7 $2.2 December 31, 2017, 2016, 2015, The Company recognized a gain (loss) from foreign currency transactions of $0.7 $0.3 $0.4 December 31, 2017, 2016, 2015, Fair Value Measurements Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may • Level 1 1 • Level 2 not • Level 3 not The Company’s financial assets have been classified as Levels 1 2. third Allowance for Doubtful Accounts The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-worthiness, current economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. A summary of activity in the allowance for doubtful accounts is as follows: December 31, 2017 2016 2015 Balance, beginning of the year $ 194 $ 167 $ 147 Amounts provided 1,609 52 38 Amounts written off (6 ) (16 ) (3 ) Translation adjustments 117 (9 ) (15 ) Balance, end of the year $ 1,914 $ 194 $ 167 Revenue Recognition - General The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists, risk of loss has passed or services have been rendered, the seller's price to the buyer is fixed or determinable, and collection from the customer is reasonably assured. Product Revenue Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual terms and conditions of its distribution and supply agreements as well as its business practices. Product revenue also includes royalties. Royalty revenue is based on distributors’ sales and is recognized in the same period distributors record their sale of products manufactured by the Company. On a quarterly basis the Company records royalty revenue based upon sales provided to it by its distributor customers. Pursuant to the Health Care and Education Reconciliation Act of 2010, January 1, 2013 605 45. 2015 no 2016 2017 2.3% January 1, 2016 2020. Licensing, Milestone and Contract Revenue Licensing, milestone and contract revenue consists of revenue recognized on initial and milestone payments, as well as contractual amounts received from partners. The Company’s business strategy includes entering into collaborative license, development, and/or supply agreements with partners for the development and commercialization of the Company’s products. Under the milestone method, the Company recognizes a consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: 1. The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone; 2. The consideration relates solely to past performance; and 3. The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the Company. Non substantive milestones are recognized when there are no The terms of the agreements typically include non-refundable license fees, funding of research and development, and payments based upon achievement of certain milestones. The Company adopted ASU 2009 13, Revenue Recognition January 2011, 605 25, Multiple Element Arrangements 605 25” 605 25, 2009 13, not Cash and Cash Equivalents The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three 90 Investments The Company’s investments consist of bank certificates of deposit with an original maturity of more than 90 three one one three All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the extent and length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not December 31, 2017 2016, not not not not Concentration of Credit Risk and Significant Customers The Company has no two The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. As of December 31, 2017 2016, 68% 66%, no 10% Inventories Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using the first first not The Company’s policy is to write-down inventory when conditions exist that suggest inventory may not When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. Inventory $22.0 and $16.0 December 31, 2017 2016, $1.7 $0.9 may Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically: Asset Estimated useful life Computer equipment and software 3 - Furniture and fixtures 5 - Equipment 5-15 years Leasehold improvements Shorter of useful life or term of lease Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no no Construction-in-process is stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process is not Goodwill and Acquired Intangible Assets Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired IPR&D represents the fair value assigned to research and development assets that the Company acquires that have not Goodwill and IPR&D are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value. To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company’s annual assessment for impairment of goodwill as of November 30, 2017 To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D projects using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not During the fourth 2015, 2015, $0.7 November 30, 2017 2016 Long-Lived Assets Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five sixteen may not no Research and Development Research and development costs consist primarily of clinical trials, salaries and related expenses for personnel, and fees paid to outside consultants and outside service providers, including costs associated with licensing, milestone and contract revenue. Research and development costs are expensed as incurred. Stock-Based Compensation The Company has stock-based compensation plans under which it grants various types of equity-based awards, including restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance options, and stock options. The Company measures the compensation cost of award recipients’ services received in exchange for an award of equity instruments based on the grant date fair value of the underlying award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award. For performance-based options with financial and business milestone achievement targets, the Company recognizes expense using the graded vesting methodology over the service period. Compensation cost associated with performance-based options is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not no $0.8 $0.3 $0.4 2017, 2016, 2015, See Note 12, Equity Incentive Plan 10 Income Taxes The Company’s income tax expense includes U.S. and international income taxes. Certain items of income and expense are not not not Comprehensive Income Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income disclosures, the Company does not Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. Based on the criteria established by ASC 280, Segment Reportin one Contingencies In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not Subsequent Events Events occurring subsequent to December 31, 2017 no Recent Accounting Pronouncements Recently Issued In May 2014, No. 2014 09, 2014 09 605, July 2015, one December 15, 2017 not January 1, 2018. The Company developed an implementation plan to assess the impact of the new guidance on its operations, financial results, and related disclosures. To date, the Company has substantially completed its assessment of the potential areas of the balance sheet and financial statement components impacted. The Company has prepared its accounting policy memorandum and assessment of the quantitative impact of adoption, including the impact of the new guidance on its results of operations and internal controls. Based on procedures performed to date, the Company has concluded that the adoption of the new standard will not not January 1, 2018. In February 2016, No. 2016 02, 842 2016 02 2016 02 December 15, 2018. may 2016 02 In June 2016, No. 2016 13, 326 2016 13 not 2016 13 January 1, 2020. not Recently Adopted In March 2016, No. 2016 09, 718 2016 09 January 1, 2017. January 1, 2017, December 31, 2016 2015, $0.6 $0.8 $0.6 $0.8 January 1, 2017, $0.5 2017. 16, Income Taxes 10

Note 3 - Investments

Note 3 - Investments	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	3. All of the Company’s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held bank certificates of deposits of $24.0 $20.5 December 31, 2017 2016, no December 31, 2017 2016.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. The Company’s investments are all classified within Levels 1 2 1 2 third not The fair value hierarchy of the Company’s cash equivalents and investments at fair value is as follows: Fair Value Measurements at Reporting Date Using December 31, 2017 Quoted Prices in Significant Other Significant Cash equivalents: Money market fund $ 5,893 $ 5,893 $ - $ - Bank certificates of deposit 500 - 500 - Total cash equivalents $ 6,393 $ 5,893 $ 500 $ - Investments: Bank certificates of deposit $ 24,000 $ - $ 24,000 $ - Fair Value Measurements at Reporting Date Using December 31, 2016 Quoted Prices in Significant Other (Level 3) Cash equivalents: Money market funds $ 68,352 $ - $ 68,352 $ - Bank certificates of deposit 750 - 750 - Total cash equivalents $ 69,102 $ - $ 69,102 $ - Investments: Bank certificates of deposit 20,500 - 20,500 - Total investments $ 20,500 $ - $ 20,500 $ - The Company did not 3 December 31, 2017 2016. December 31, 2017, 1 2

Note 5 - Earnings Per Share ("E

Note 5 - Earnings Per Share ("EPS")	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested RSA’s, although legally issued and outstanding, are not The following table provides share information used in the calculation of the Company's basic and diluted earnings per share: Years Ended December 31, 2017 2016 2015 Shares used in the calculation of basic earnings per share 14,575 14,682 14,934 Effect of dilutive securities: Stock options, SAR's, RSA's and RSU's 493 434 387 Diluted shares used in the calculation of earnings per share 15,068 15,116 15,321 Stock options to purchase 0.5 0.4 0.2 December 31, 2017, 2016, 2015, 2017, 2016 2015 not At December 31, 2017, 2016, 2015, 0.1 On February 26, 2016, $25.0 $25.0 0.4 February 29, 2016 $46.40 On August 26, 2016, $7.5 August 26, 2016. 0.1 August 31, 2016. 0.5 $47.08

Note 6 - Inventories

Note 6 - Inventories	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventories consist of the following: December 31, 2017 2016 Raw materials $ 11,296 $ 5,884 Work-in-process 6,062 5,559 Finished goods 4,677 4,540 Total $ 22,035 $ 15,983

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	7. Property and equipment is stated at cost and consists of the following: December 31, 2017 2016 Equipment and software $ 37,137 $ 27,456 Furniture and fixtures 1,947 1,126 Leasehold improvements 31,459 27,796 Construction in progress 5,830 22,695 Subtotal 76,373 79,073 Less accumulated depreciation (20,190 ) (26,777 ) Total $ 56,183 $ 52,296 Construction-in-progress at December 31, 2017, January 2018. December 31, 2016 2015 December 2017. 2017 $9.8 no Depreciation expense was $3.3 $2.7 $2.7 December 31, 2017, 2016, 2015,

Note 8 - Acquired Intangible As

Note 8 - Acquired Intangible Assets, Net	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	8. Intangible assets consist of the following: December 31, 2017 December 31, 2016 Gross Value Accumulated Accumulated Net Book Accumulated Accumulated Net Book Useful Developed technology $ 17,100 $ (2,550 ) $ (7,723 ) $ 6,827 $ (3,442 ) $ (6,816 ) $ 6,842 15 In-process research & development 4,406 (1,015 ) 3,391 (1,433 ) - 2,973 Indefinite Distributor relationships 4,700 (415 ) (4,285 ) - (415 ) (4,285 ) - 5 Patents 1,000 (152 ) (431 ) 417 (207 ) (381 ) 412 16 Elevess trade name 1,000 - (1,000 ) - - (1,000 ) - 9 Total $ 28,206 $ (4,132 ) $ (13,439 ) $ 10,635 $ (5,497 ) $ (12,482 ) $ 10,227 On December 30, 2009, In 2015, $0.7 fourth The Company performed an annual assessment of IPR&D intangible assets as of November 30, 2017. 2017 no Total amortization expense was $1.0 $1.1 $1.1 December 31, 2017, 2016, 2015, $1.0 2018, $1.0 2021, $3.1

Note 9 - Goodwill

Note 9 - Goodwill	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Goodwill Disclosure [Text Block]	9. The Company completed its annual impairment review as of November 30, 2017 no December 31, 2017, not may not December 31, 2017 2016 Balance, beginning $ 7,214 $ 7,482 Effect of foreign currency adjustments 1,004 (268 ) Balance, ending $ 8,218 $ 7,214

Note 10 - Accrued Expenses

Note 10 - Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	10. Accrued expenses consist of the following: December 31, 2017 2016 Compensation and related expenses $ 2,893 $ 3,089 Facility construction costs - 804 Research grants 419 463 Clinical trial costs 2,318 227 Professional fees 448 802 Deferred rent - 231 Other 248 880 Total $ 6,326 $ 6,496

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Leasing Arrangements On October 9, 2015, 33,000 fifteen March 1, 2017. three six six no ninth $0.3 Construction of the new facility commenced during the first 2016. March 1, 2017, $3.1 $0.8 Prior to April 2017, 28,000 December 29, 2016 March 31, 2017. Rental expense in connection with the various facility leases totaled $1.8 $1.3 $1.3 December 31, 2017, 2016, 2015, 2017 first November 1, 2017 October 31, 2022, The Company’s future lease commitments as of December 31, 2017 2018 $ 1,879 2019 1,880 2020 1,916 2021 1,924 2022 1,673 2023 and thereafter 1,311 Total $ 10,583 Warranty and Guarantor Arrangements In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third no December 31, 2017 2016, no Legal Proceedings The Company is involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of potential legal proceedings are inherently difficult to predict, the Company does not

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12. Equity Incentive Plan The Anika Therapeutics, Inc. Stock Option and Incentive Plan, as amended, (the “2003 2003 April 4, 2003, June 4, 2003, 1,500,000 On May 29, 2009, 2003 2003 2003 850,000. 2003 June 5, 2009, 2,350,000 2003 At the 2011 June 7, 2011, “2003 800,000 3,150,000 2003 June 7, 2011 1.9 At the 2013 June 18, 2013, 2003 650,000 3,800,000 2003 June 18, 2013 1.5 On June 13, 2017, 2017 “2017 2017 2003 2017 March 31, 2017. 2017 may 2017 2.0 no 1.2 may 2017 1.1 December 31, 2017. The Company may one four The Company estimates the fair value of stock options and SAR’s using the Black-Scholes valuation model. Fair value of restricted stock is measured by the grant-date price of the Company’s shares. Key input assumptions used to estimate the fair value of stock options and SAR’s include the exercise price of the award, the expected award term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the award’s expected term, and the Company’s expected annual dividend yield. The expected volatility assumption is evaluated against the historical volatility of the Company’s common stock over a four The fair value of each stock option during 2017, 2016, 2015 2017 2016 2015 Risk free interest rate 1.60% - 1.86% 0.94% - 1.55% 1.15% - 1.46% Expected volatility 38.74% - 44.31% 47.33% - 51.61% 53.15% - 54.65% Expected life (years) 4.0 4.5 4.5 Expected dividend yield 0.00% 0.00% 0.00% Stock Options and Restricted Stock During the year ended December 31, 2017, 85,109 26,306 2017 407,635 2003 three January 2017, 2003 9,970 one The Company recorded $5.8 $3.4 $2.2 December 31, 2017, 2016, 2015, 2017 2016 2015 Cost of product revenue $ 439 $ 148 $ 42 Research & development 564 467 269 Selling, general & administrative 4,804 2,777 1,914 Total stock-based compensation expense $ 5,807 $ 3,392 $ 2,225 Combined stock options and SAR’s activity under the Company’s plans is summarized as follows for the years ended December 31, 2017 2016, 2017 2016 Weighted Weighted Average Average Exercise Exercise Number of Price Per Number of Price Per Shares Share Shares Share Options and SAR's outstanding at beginning of year 979,569 $ 26.15 762,260 $ 18.75 Granted 440,688 $ 50.22 354,275 $ 40.77 Cancelled (74,527 ) $ 45.56 (58,841 ) $ 30.05 Expired (589 ) $ 32.86 (3,310 ) $ 11.37 Exercised (17,941 ) $ 20.56 (74,815 ) $ 15.46 Options and SAR's outstanding at end of year 1,327,200 $ 33.70 979,569 $ 26.15 All the 1,327,200 December 31, 2017 $33.70 $27.6 7.0 December 31, 2017. As of December 31, 2017, $7.6 2.1 The exercisable options and SAR’s at December 31, 2017 Outstanding Weighted Average Weighted Average Incentive stock options 182,472 $ 14.12 4.3 Nonqualified stock options 374,211 $ 20.18 5.3 Performance options 32,598 $ 38.79 7.7 SAR's 35,250 $ 6.36 2.1 The aggregate intrinsic value of stock options and SAR’s fully vested at December 31, 2017 2016 $22.0 $16.7 December 31, 2017 2016 $27.6 $22.3 The total intrinsic value of stock options and SAR’s exercised was $0.5 $2.1 December 31, 2017 2016, The total fair value of stock options and SAR’s vested during the years ended December 31, 2017 2016 $2.1 $1.3 The Company received $0.3 $1.0 December 31, 2017 2016, The RSA and RSU activity for the years ended December 31, 2017 2016 2017 2016 Weighted Weighted Average Average Number of Grant Date Number of Grant Date Shares Fair Value Shares Fair Value Unvested at Beginning of year 207,077 $ 36.44 150,384 $ 34.29 Granted 67,567 $ 52.03 87,158 $ 38.11 Cancelled - $ - (4,950 ) $ 36.20 Expired - $ - - $ - Vested/Released (45,418 ) $ 35.32 (25,515 ) $ 33.35 Unvested at end of year 229,226 $ 42.47 207,077 $ 36.44 The total fair value of RSA’s and RSU’s vested during the years ended December 31, 2017 2016 $2.3 $1.0

Note 13 - Employee Benefit Plan

Note 13 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	13. The Company’s U.S. employees are eligible to participate in the Company’s 401 may 140% 5% may $0.6 $0.6 $0.4 December 31, 2017, 2016, 2015,

Note 14 - Shareholder Rights Pl

Note 14 - Shareholder Rights Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	14. On April 4, 2008, “2008 2008 ( 1 15% ( 2 15% In the event that a person becomes an “Acquiring Person,” each holder of a Right (other than the Acquiring Person) would be entitled to acquire a number of shares of preferred stock equivalent to shares of the Company’s common stock having a value of twice the exercise price of the Right. If, after any such event, the Company enters into a merger or other business combination transaction with another entity, each holder of a Right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the exercise price of the Right. The current exercise price per Right is $75.00. may not $0.01 ( 1 ( 2 At any time after any person becomes an “Acquiring Person,” the Board of Directors may, 2008 not 50% In connection with the establishment of the 2008 $0.01 175,000 no

Note 15 - Revenue by Product Gr

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. Product revenue by product group is as follows: Years Ended December 31, 2017 2016 2015 Revenue Percentage of Product Revenue Revenue Percentage of Product Revenue Revenue Percentage of Product Revenue Orthobiologics $ 93,816 87 % $ 89,695 87 % $ 73,247 84 % Dermal 2,755 3 % 2,759 3 % 2,266 2 % Surgical 5,262 5 % 5,427 5 % 5,812 7 % Other 5,950 5 % 5,051 5 % 6,371 7 % $ 107,783 100 % $ 102,932 100 % $ 87,696 100 % Product revenue from our sole significant customer, Mitek, as a percentage of our total product revenue was 73%, 75%, 72% December 31, 2017, 2016, 2015, ORTHOVISC became available for sale in the United States on March 1, 2004, ten December 2003. five 2012 2017, December 20, 2023. In December 2011, fifteen December 31, 2017, 2016, 2015, $5.0 $0.0 $5.0 2015 $50 12 2017 $100 12 may Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows: Years Ended December 31, 2017 2016 2015 Total Percentage of Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Revenue Revenue Geographic Location: United States $ 92,905 82 % $ 83,972 81 % $ 76,621 82 % Europe 12,435 11 % 10,953 11 % 8,756 9 % Other 8,080 7 % 8,454 8 % 7,622 9 % Total $ 113,420 100 % $ 103,379 100 % $ 92,999 100 % The Company recorded licensing, milestone, and contract revenue of $5.6 $0.4 $5.3 December 31, 2017, 2016, 2015, 2016 Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows: Years Ended December 31, 2017 2016 United States $ 52,828 $ 49,140 Italy 3,355 3,156 Total $ 56,183 $ 52,296

Note 16 - Income Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	16. New Tax Legislation On December 22, 2017, “2017 35% 21% 2018. $2.3 2017 not 2017 In accordance with Staff Accounting Bulletin No. 118, 2017 2017 not Income Tax Expense The components of the Company’s income before income taxes and its provision for (benefit from) income taxes consist of the following: Years ended December 31, 2017 2016 2015 Income before income taxes Domestic $ 48,446 $ 50,181 $ 48,608 Foreign (2,244 ) 689 (354 ) $ 46,202 $ 50,870 $ 48,254 Years ended December 31, 2017 2016 2015 Provision for (benefit from) income taxes: Current provision: Federal $ 12,608 $ 14,982 $ 14,572 State 2,737 3,265 3,635 Foreign 31 302 249 15,376 18,549 18,456 Deferred provision: Federal (426 ) (70 ) (370 ) State (68 ) (84 ) (33 ) Foreign (496 ) (72 ) (557 ) (990 ) (226 ) (960 ) Total provision $ 14,386 $ 18,323 $ 17,496 Deferred Tax Assets and Liabilities Significant components of the Company’s deferred tax assets and liabilities consist of the following: December 31, 2017 2016 Deferred tax assets: Net operating loss carry forward, foreign $ 959 $ 1,253 Stock-based compensation expense 2,309 1,882 Foreign currency exchange 265 677 Accrued expenses and other 496 308 Inventory reserve 740 640 Deferred tax assets $ 4,769 $ 4,760 December 31, 2017 2016 Deferred tax liabilities: Acquisition-related Intangibles $ (2,743 ) $ (2,932 ) Depreciation (7,419 ) (8,376 ) Deferred tax liabilities $ (10,162 ) $ (11,308 ) Net deferred tax liabilities $ (5,393 ) $ (6,548 ) Tax Rate The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as follows: Years ended December 31, 2017 2016 2015 Statutory federal income tax rate 35.0 % 35.0 % 35.0 % State tax expense, net of federal benefit 4.8 % 4.5 % 4.8 % Impact of rate change on deferred taxes (4.9 %) 0.0 % 0.0 % Permanent items, including nondeductible expenses 0.6 % 0.5 % (0.3 %) State investment tax credit (0.7 %) (0.1 %) 0.0 % Federal, state and foreign research and development credits (1.4 %) (0.9 %) (0.4 %) Foreign rate differential 0.5 % (0.1 %) 0.1 % Domestic production deduction (2.8 %) (2.9 %) (2.9 %) Effective income tax rate 31.1 % 36.0 % 36.3 % As of December 31, 2017, $4.0 not Accounting for Uncertainty in Income Taxes The Company had no December 31, 2017 2016, The Company does not twelve December 31, 2017. In the normal course of business, Anika and its subsidiaries may 2014 2016 2011 2016 Upon the settlement of certain stock-based awards (i.e., exercise, vesting, forfeiture, or cancellation), the actual tax deduction is compared with cumulative financial reporting compensation cost, and any excess tax deduction related to these awards is considered a windfall tax benefit. With the adoption of ASU 2016 09 2017, 2016 09, $0.4 2017. $0.6 $0.9 2016 2015,

Note 17 - Revolving Credit Agre

Note 17 - Revolving Credit Agreement	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	17. On October 24, 2017, five $50.0 may $50.0 $100.0 0.50%, one 1.0%, 0.25% 1.75% 0.25% five December 31, 2017, no The Credit Agreement contains customary representations, warranties, affirmative and negative covenants, including financial covenants, events of default and indemnification provisions in favor of the Lenders (as defined in the Credit Agreement). The covenants include restrictions governing the Company’s leverage ratio and interest coverage ratio, its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and other matters, all subject to certain exceptions. The financial covenants require the Company not first

Note 18 - Quarterly Financial D

Note 18 - Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	18. Quarter ended Quarter ended Quarter ended Quarter ended Year 2017 December 31 September 30 June 30 March 31 Product revenue $ 28,884 $ 27,178 $ 28,340 $ 23,381 Total revenue 29,388 27,184 33,462 23,386 Cost of product revenue 8,716 6,250 6,315 6,083 Gross profit on product revenue 20,168 20,928 22,025 17,298 Net income $ 8,067 $ 6,887 $ 11,369 $ 5,493 Per common share information: Basic net income per share $ 0.55 $ 0.47 $ 0.78 $ 0.38 Basic common shares outstanding 14,596 14,579 14,588 14,576 Diluted net income per share $ 0.53 $ 0.46 $ 0.76 $ 0.37 Diluted common shares outstanding 15,141 15,115 15,044 15,043 Quarter ended Quarter ended Quarter ended Quarter ended Year 2016 December 31 September 30 June 30 March 31 Product revenue $ 28,296 $ 25,783 $ 26,575 $ 22,278 Total revenue 28,726 25,789 26,581 22,283 Cost of product revenue 7,539 4,998 6,065 5,425 Gross profit on product revenue 20,757 20,785 20,510 16,853 Net income $ 8,085 $ 8,952 $ 8,615 $ 6,895 Per common share information: Basic net income per share $ 0.56 $ 0.61 $ 0.59 $ 0.46 Basic common shares outstanding 14,538 14,625 14,679 14,875 Diluted net income per share $ 0.54 $ 0.59 $ 0.57 $ 0.45 Diluted common shares outstanding 14,979 15,077 15,111 15,307

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. All intercompany balances and transactions have been eliminated in consolidation.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company’s foreign subsidiary is the Euro. Assets and liabilities of the foreign subsidiary are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive loss which resulted in a gain (loss) from foreign currency translation of $2.5 $0.7 $2.2 December 31, 2017, 2016, 2015, The Company recognized a gain (loss) from foreign currency transactions of $0.7 $0.3 $0.4 December 31, 2017, 2016, 2015,
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may • Level 1 1 • Level 2 not • Level 3 not The Company’s financial assets have been classified as Levels 1 2. third
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance for doubtful accounts, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer credit-worthiness, current economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. A summary of activity in the allowance for doubtful accounts is as follows: December 31, 2017 2016 2015 Balance, beginning of the year $ 194 $ 167 $ 147 Amounts provided 1,609 52 38 Amounts written off (6 ) (16 ) (3 ) Translation adjustments 117 (9 ) (15 ) Balance, end of the year $ 1,914 $ 194 $ 167
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition - General The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists, risk of loss has passed or services have been rendered, the seller's price to the buyer is fixed or determinable, and collection from the customer is reasonably assured.
Revenue Recognition, Sales of Goods [Policy Text Block]	Product Revenue Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual terms and conditions of its distribution and supply agreements as well as its business practices. Product revenue also includes royalties. Royalty revenue is based on distributors’ sales and is recognized in the same period distributors record their sale of products manufactured by the Company. On a quarterly basis the Company records royalty revenue based upon sales provided to it by its distributor customers. Pursuant to the Health Care and Education Reconciliation Act of 2010, January 1, 2013 605 45. 2015 no 2016 2017 2.3% January 1, 2016 2020.
Revenue Recognition, Services, Licensing Fees [Policy Text Block]	Licensing, Milestone and Contract Revenue Licensing, milestone and contract revenue consists of revenue recognized on initial and milestone payments, as well as contractual amounts received from partners. The Company’s business strategy includes entering into collaborative license, development, and/or supply agreements with partners for the development and commercialization of the Company’s products. Under the milestone method, the Company recognizes a consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: 1. The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone; 2. The consideration relates solely to past performance; and 3. The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the Company. Non substantive milestones are recognized when there are no The terms of the agreements typically include non-refundable license fees, funding of research and development, and payments based upon achievement of certain milestones. The Company adopted ASU 2009 13, Revenue Recognition January 2011, 605 25, Multiple Element Arrangements 605 25” 605 25, 2009 13, not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three 90
Marketable Securities, Policy [Policy Text Block]	Investments The Company’s investments consist of bank certificates of deposit with an original maturity of more than 90 three one one three All of the Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the extent and length of time the investment's fair value has been lower than its cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, the Company’s intent to sell the security, and whether or not December 31, 2017 2016, not not not not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Significant Customers The Company has no two The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. As of December 31, 2017 2016, 68% 66%, no 10%
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of standard cost and net realizable value, with approximate cost determined using the first first not The Company’s policy is to write-down inventory when conditions exist that suggest inventory may not When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. Inventory $22.0 and $16.0 December 31, 2017 2016, $1.7 $0.9 may
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically: Asset Estimated useful life Computer equipment and software 3 - Furniture and fixtures 5 - Equipment 5-15 years Leasehold improvements Shorter of useful life or term of lease Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no no Construction-in-process is stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process is not
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Acquired Intangible Assets Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired IPR&D represents the fair value assigned to research and development assets that the Company acquires that have not Goodwill and IPR&D are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. Factors the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value. To conduct impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company’s annual assessment for impairment of goodwill as of November 30, 2017 To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D projects using discounted cash flow valuation models, which require the use of significant estimates and assumptions, including but not During the fourth 2015, 2015, $0.7 November 30, 2017 2016
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, and trade names. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five sixteen may not no
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs consist primarily of clinical trials, salaries and related expenses for personnel, and fees paid to outside consultants and outside service providers, including costs associated with licensing, milestone and contract revenue. Research and development costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company has stock-based compensation plans under which it grants various types of equity-based awards, including restricted stock units (“RSUs”), restricted stock awards (“RSAs”), performance options, and stock options. The Company measures the compensation cost of award recipients’ services received in exchange for an award of equity instruments based on the grant date fair value of the underlying award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award. For performance-based options with financial and business milestone achievement targets, the Company recognizes expense using the graded vesting methodology over the service period. Compensation cost associated with performance-based options is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not no $0.8 $0.3 $0.4 2017, 2016, 2015, See Note 12, Equity Incentive Plan 10
Income Tax, Policy [Policy Text Block]	Income Taxes The Company’s income tax expense includes U.S. and international income taxes. Certain items of income and expense are not not not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income disclosures, the Company does not
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. Based on the criteria established by ASC 280, Segment Reportin one
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events Events occurring subsequent to December 31, 2017 no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Issued In May 2014, No. 2014 09, 2014 09 605, July 2015, one December 15, 2017 not January 1, 2018. The Company developed an implementation plan to assess the impact of the new guidance on its operations, financial results, and related disclosures. To date, the Company has substantially completed its assessment of the potential areas of the balance sheet and financial statement components impacted. The Company has prepared its accounting policy memorandum and assessment of the quantitative impact of adoption, including the impact of the new guidance on its results of operations and internal controls. Based on procedures performed to date, the Company has concluded that the adoption of the new standard will not not January 1, 2018. In February 2016, No. 2016 02, 842 2016 02 2016 02 December 15, 2018. may 2016 02 In June 2016, No. 2016 13, 326 2016 13 not 2016 13 January 1, 2020. not Recently Adopted In March 2016, No. 2016 09, 718 2016 09 January 1, 2017. January 1, 2017, December 31, 2016 2015, $0.6 $0.8 $0.6 $0.8 January 1, 2017, $0.5 2017. 16, Income Taxes 10

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Allowance for Credit Losses on Financing Receivables [Table Text Block]	December 31, 2017 2016 2015 Balance, beginning of the year $ 194 $ 167 $ 147 Amounts provided 1,609 52 38 Amounts written off (6 ) (16 ) (3 ) Translation adjustments 117 (9 ) (15 ) Balance, end of the year $ 1,914 $ 194 $ 167
Property, Plant and Equipment Estimated Useful Lives [Table Text Block]	Asset Estimated useful life Computer equipment and software 3 - Furniture and fixtures 5 - Equipment 5-15 years Leasehold improvements Shorter of useful life or term of lease

Note 4 - Fair Value Measureme27

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using December 31, 2017 Quoted Prices in Significant Other Significant Cash equivalents: Money market fund $ 5,893 $ 5,893 $ - $ - Bank certificates of deposit 500 - 500 - Total cash equivalents $ 6,393 $ 5,893 $ 500 $ - Investments: Bank certificates of deposit $ 24,000 $ - $ 24,000 $ - Fair Value Measurements at Reporting Date Using December 31, 2016 Quoted Prices in Significant Other (Level 3) Cash equivalents: Money market funds $ 68,352 $ - $ 68,352 $ - Bank certificates of deposit 750 - 750 - Total cash equivalents $ 69,102 $ - $ 69,102 $ - Investments: Bank certificates of deposit 20,500 - 20,500 - Total investments $ 20,500 $ - $ 20,500 $ -

Note 5 - Earnings Per Share (28

Note 5 - Earnings Per Share ("EPS") (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, 2017 2016 2015 Shares used in the calculation of basic earnings per share 14,575 14,682 14,934 Effect of dilutive securities: Stock options, SAR's, RSA's and RSU's 493 434 387 Diluted shares used in the calculation of earnings per share 15,068 15,116 15,321

Note 6 - Inventories (Tables)

Note 6 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2017 2016 Raw materials $ 11,296 $ 5,884 Work-in-process 6,062 5,559 Finished goods 4,677 4,540 Total $ 22,035 $ 15,983

Note 7 - Property and Equipme30

Note 7 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2017 2016 Equipment and software $ 37,137 $ 27,456 Furniture and fixtures 1,947 1,126 Leasehold improvements 31,459 27,796 Construction in progress 5,830 22,695 Subtotal 76,373 79,073 Less accumulated depreciation (20,190 ) (26,777 ) Total $ 56,183 $ 52,296

Note 8 - Acquired Intangible 31

Note 8 - Acquired Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	December 31, 2017 December 31, 2016 Gross Value Accumulated Accumulated Net Book Accumulated Accumulated Net Book Useful Developed technology $ 17,100 $ (2,550 ) $ (7,723 ) $ 6,827 $ (3,442 ) $ (6,816 ) $ 6,842 15 In-process research & development 4,406 (1,015 ) 3,391 (1,433 ) - 2,973 Indefinite Distributor relationships 4,700 (415 ) (4,285 ) - (415 ) (4,285 ) - 5 Patents 1,000 (152 ) (431 ) 417 (207 ) (381 ) 412 16 Elevess trade name 1,000 - (1,000 ) - - (1,000 ) - 9 Total $ 28,206 $ (4,132 ) $ (13,439 ) $ 10,635 $ (5,497 ) $ (12,482 ) $ 10,227

Note 9 - Goodwill (Tables)

Note 9 - Goodwill (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Goodwill [Table Text Block]	December 31, 2017 2016 Balance, beginning $ 7,214 $ 7,482 Effect of foreign currency adjustments 1,004 (268 ) Balance, ending $ 8,218 $ 7,214

Note 10 - Accrued Expenses (Tab

Note 10 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2017 2016 Compensation and related expenses $ 2,893 $ 3,089 Facility construction costs - 804 Research grants 419 463 Clinical trial costs 2,318 227 Professional fees 448 802 Deferred rent - 231 Other 248 880 Total $ 6,326 $ 6,496

Note 11 - Commitments and Con34

Note 11 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 $ 1,879 2019 1,880 2020 1,916 2021 1,924 2022 1,673 2023 and thereafter 1,311 Total $ 10,583

Note 12 - Equity Incentive Pl35

Note 12 - Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2017 2016 2015 Risk free interest rate 1.60% - 1.86% 0.94% - 1.55% 1.15% - 1.46% Expected volatility 38.74% - 44.31% 47.33% - 51.61% 53.15% - 54.65% Expected life (years) 4.0 4.5 4.5 Expected dividend yield 0.00% 0.00% 0.00%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2017 2016 2015 Cost of product revenue $ 439 $ 148 $ 42 Research & development 564 467 269 Selling, general & administrative 4,804 2,777 1,914 Total stock-based compensation expense $ 5,807 $ 3,392 $ 2,225
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]	2017 2016 Weighted Weighted Average Average Exercise Exercise Number of Price Per Number of Price Per Shares Share Shares Share Options and SAR's outstanding at beginning of year 979,569 $ 26.15 762,260 $ 18.75 Granted 440,688 $ 50.22 354,275 $ 40.77 Cancelled (74,527 ) $ 45.56 (58,841 ) $ 30.05 Expired (589 ) $ 32.86 (3,310 ) $ 11.37 Exercised (17,941 ) $ 20.56 (74,815 ) $ 15.46 Options and SAR's outstanding at end of year 1,327,200 $ 33.70 979,569 $ 26.15
Schedule of Share-based Compensation, Exercisable Stock Options and Stock Appreciation Rights Award Activity [Table Text Bloc]	Outstanding Weighted Average Weighted Average Incentive stock options 182,472 $ 14.12 4.3 Nonqualified stock options 374,211 $ 20.18 5.3 Performance options 32,598 $ 38.79 7.7 SAR's 35,250 $ 6.36 2.1
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	2017 2016 Weighted Weighted Average Average Number of Grant Date Number of Grant Date Shares Fair Value Shares Fair Value Unvested at Beginning of year 207,077 $ 36.44 150,384 $ 34.29 Granted 67,567 $ 52.03 87,158 $ 38.11 Cancelled - $ - (4,950 ) $ 36.20 Expired - $ - - $ - Vested/Released (45,418 ) $ 35.32 (25,515 ) $ 33.35 Unvested at end of year 229,226 $ 42.47 207,077 $ 36.44

Note 15 - Revenue by Product 36

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Years Ended December 31, 2017 2016 2015 Revenue Percentage of Product Revenue Revenue Percentage of Product Revenue Revenue Percentage of Product Revenue Orthobiologics $ 93,816 87 % $ 89,695 87 % $ 73,247 84 % Dermal 2,755 3 % 2,759 3 % 2,266 2 % Surgical 5,262 5 % 5,427 5 % 5,812 7 % Other 5,950 5 % 5,051 5 % 6,371 7 % $ 107,783 100 % $ 102,932 100 % $ 87,696 100 %
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Years Ended December 31, 2017 2016 2015 Total Percentage of Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Revenue Revenue Geographic Location: United States $ 92,905 82 % $ 83,972 81 % $ 76,621 82 % Europe 12,435 11 % 10,953 11 % 8,756 9 % Other 8,080 7 % 8,454 8 % 7,622 9 % Total $ 113,420 100 % $ 103,379 100 % $ 92,999 100 %
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Years Ended December 31, 2017 2016 United States $ 52,828 $ 49,140 Italy 3,355 3,156 Total $ 56,183 $ 52,296

Note 16 - Income Taxes (Tables)

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years ended December 31, 2017 2016 2015 Income before income taxes Domestic $ 48,446 $ 50,181 $ 48,608 Foreign (2,244 ) 689 (354 ) $ 46,202 $ 50,870 $ 48,254 Years ended December 31, 2017 2016 2015 Provision for (benefit from) income taxes: Current provision: Federal $ 12,608 $ 14,982 $ 14,572 State 2,737 3,265 3,635 Foreign 31 302 249 15,376 18,549 18,456 Deferred provision: Federal (426 ) (70 ) (370 ) State (68 ) (84 ) (33 ) Foreign (496 ) (72 ) (557 ) (990 ) (226 ) (960 ) Total provision $ 14,386 $ 18,323 $ 17,496
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2017 2016 Deferred tax assets: Net operating loss carry forward, foreign $ 959 $ 1,253 Stock-based compensation expense 2,309 1,882 Foreign currency exchange 265 677 Accrued expenses and other 496 308 Inventory reserve 740 640 Deferred tax assets $ 4,769 $ 4,760 December 31, 2017 2016 Deferred tax liabilities: Acquisition-related Intangibles $ (2,743 ) $ (2,932 ) Depreciation (7,419 ) (8,376 ) Deferred tax liabilities $ (10,162 ) $ (11,308 ) Net deferred tax liabilities $ (5,393 ) $ (6,548 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years ended December 31, 2017 2016 2015 Statutory federal income tax rate 35.0 % 35.0 % 35.0 % State tax expense, net of federal benefit 4.8 % 4.5 % 4.8 % Impact of rate change on deferred taxes (4.9 %) 0.0 % 0.0 % Permanent items, including nondeductible expenses 0.6 % 0.5 % (0.3 %) State investment tax credit (0.7 %) (0.1 %) 0.0 % Federal, state and foreign research and development credits (1.4 %) (0.9 %) (0.4 %) Foreign rate differential 0.5 % (0.1 %) 0.1 % Domestic production deduction (2.8 %) (2.9 %) (2.9 %) Effective income tax rate 31.1 % 36.0 % 36.3 %

Note 18 - Quarterly Financial38

Note 18 - Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	Quarter ended Quarter ended Quarter ended Quarter ended Year 2017 December 31 September 30 June 30 March 31 Product revenue $ 28,884 $ 27,178 $ 28,340 $ 23,381 Total revenue 29,388 27,184 33,462 23,386 Cost of product revenue 8,716 6,250 6,315 6,083 Gross profit on product revenue 20,168 20,928 22,025 17,298 Net income $ 8,067 $ 6,887 $ 11,369 $ 5,493 Per common share information: Basic net income per share $ 0.55 $ 0.47 $ 0.78 $ 0.38 Basic common shares outstanding 14,596 14,579 14,588 14,576 Diluted net income per share $ 0.53 $ 0.46 $ 0.76 $ 0.37 Diluted common shares outstanding 15,141 15,115 15,044 15,043 Quarter ended Quarter ended Quarter ended Quarter ended Year 2016 December 31 September 30 June 30 March 31 Product revenue $ 28,296 $ 25,783 $ 26,575 $ 22,278 Total revenue 28,726 25,789 26,581 22,283 Cost of product revenue 7,539 4,998 6,065 5,425 Gross profit on product revenue 20,757 20,785 20,510 16,853 Net income $ 8,085 $ 8,952 $ 8,615 $ 6,895 Per common share information: Basic net income per share $ 0.56 $ 0.61 $ 0.59 $ 0.46 Basic common shares outstanding 14,538 14,625 14,679 14,875 Diluted net income per share $ 0.54 $ 0.59 $ 0.57 $ 0.45 Diluted common shares outstanding 14,979 15,077 15,111 15,307

Note 2 - Summary of Significa39

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 2,500	$ (700)	$ (2,200)
Foreign Currency Transaction Gain (Loss), before Tax	$ 700	$ (300)	$ (400)
Concentration Risk, Percentage	100.00%	100.00%	100.00%
Inventory, Net	$ 22,035	$ 15,983
Inventory Adjustments	1,700	900
Allocated Share-based Compensation Expense	5,807	3,392	$ 2,225
Reclassification from Net Cash Used in Financing Activities to Net Cash Provided by Operating Activities [Member] | Year Ended December 31, 2016 [Member]
Prior Period Reclassification Adjustment	600
Reclassification from Net Cash Used in Financing Activities to Net Cash Provided by Operating Activities [Member] | Year Ended December 31, 2015 [Member]
Prior Period Reclassification Adjustment	800
Performance Shares [Member]
Allocated Share-based Compensation Expense	800	300	400
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 564	$ 467	269
In Process Research Development [Member] | Research and Development Expense [Member]
Impairment of Intangible Assets, Finite-lived			$ 700
Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	16 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	54 years
Accounts Receivable [Member] | Customer Concentration Risk [Member] | DePuy Mitek Inc [Member]
Concentration Risk, Percentage	68.00%	66.00%

Note 2 - Summary of Significa40

Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance, beginning of the year	$ 194	$ 167	$ 147
Provision for doubtful accounts	1,609	52	38
Amounts written off	(6)	(16)	(3)
Translation adjustments	117	(9)	(15)
Balance, end of the year	$ 1,914	$ 194	$ 167

Note 2 - Summary of Significa41

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Estimated useful life (Year)	5 years
Minimum [Member] | Computer Equipment and Software [Member]
Estimated useful life (Year)	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years
Minimum [Member] | Equipment [Member]
Estimated useful life (Year)	5 years
Maximum [Member]
Estimated useful life (Year)	16 years
Maximum [Member] | Computer Equipment and Software [Member]
Estimated useful life (Year)	5 years
Maximum [Member] | Furniture and Fixtures [Member]
Estimated useful life (Year)	7 years
Maximum [Member] | Equipment [Member]
Estimated useful life (Year)	15 years

Note 3 - Investments (Details T

Note 3 - Investments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax	$ 0	$ 0
Certificates of Deposit [Member]
Available-for-sale Securities	$ 24,000	$ 20,500

Note 4 - Fair Value Measureme43

Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Money market fund	$ 6,393	$ 69,102
Investments	24,000	20,500
Fair Value, Inputs, Level 1 [Member]
Money market fund	5,893
Investments
Fair Value, Inputs, Level 2 [Member]
Money market fund	500	69,102
Investments		20,500
Fair Value, Inputs, Level 3 [Member]
Money market fund
Investments
Mutual Funds [Member]
Money market fund	5,893
Mutual Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market fund	5,893
Mutual Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market fund
Mutual Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market fund
Money Market Funds [Member]
Money market fund		68,352
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market fund
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market fund		68,352
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market fund
Certificates of Deposit [Member]
Money market fund	500	750
Investments	24,000	20,500
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Money market fund
Investments
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Money market fund	500	750
Investments	24,000	20,500
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Money market fund
Investments

Note 5 - Earnings Per Share (44

Note 5 - Earnings Per Share ("EPS") (Details Textual) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Aug. 31, 2016	Feb. 29, 2016	Feb. 26, 2016	Aug. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 26, 2016
Payments for Repurchase of Common Stock						$ 25,000
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member]
Payments for Repurchase of Common Stock			$ 25,000
Stock Repurchased and Retired During Period, Shares	0.1	0.4		0.5
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member] | Common Stock [Member]
Stock Repurchase Program, Authorized Amount			$ 25,000
Accelerated Share Repurchases, Initial Price Paid Per Share		$ 46.40
Accelerated Share Repurchases, Settlement (Payment) or Receipt								$ 7,500
Accelerated Share Repurchases, Final Price Paid Per Share				$ 47.08
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					0.5	0.4	0.2
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					0.1	0.1	0.1

Note 5 - Earnings Per Share (45

Note 5 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Basic weighted average common shares outstanding (in shares)									14,575	14,682	14,934
Effect of dilutive securities:
Stock options, SAR's, RSA's and RSU's (in shares)									493	434	387
Diluted shares used in the calculation of earnings per share (in shares)	15,141	15,115	15,044	15,043	14,979	15,077	15,111	15,307	15,068	15,116	15,321

Note 6 - Inventories - Summary

Note 6 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Raw materials	$ 11,296	$ 5,884
Work-in-process	6,062	5,559
Finished goods	4,677	4,540
Total	$ 22,035	$ 15,983

Note 7 - Property and Equipme47

Note 7 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Disposals	$ 9.8
Depreciation	$ 3.3	$ 2.7	$ 2.7

Note 7 - Property and Equipme48

Note 7 - Property and Equipment - Property and Equipment at Cost (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, plant and equipment, gross	$ 76,373	$ 79,073
Less accumulated depreciation	(20,190)	(26,777)
Total	56,183	52,296
Equipment and Software [Member]
Property, plant and equipment, gross	37,137	27,456
Furniture and Fixtures [Member]
Property, plant and equipment, gross	1,947	1,126
Leasehold Improvements [Member]
Property, plant and equipment, gross	31,459	27,796
Construction in Progress [Member]
Property, plant and equipment, gross	$ 5,830	$ 22,695

Note 8 - Acquired Intangible 49

Note 8 - Acquired Intangible Assets, Net (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Amortization of Intangible Assets	$ 1	$ 1.1	$ 1.1
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	1
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1
Finite-Lived Intangible Assets, Amortization Expense, Year Five	3.1
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$ 1
In Process Research Development [Member] | Research and Development Expense [Member]
Impairment of Intangible Assets, Finite-lived			$ 0.7

Note 8 - Intangible Assets - Su

Note 8 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Gross Value	$ 28,206
Accumulated Currency Translation Adjustment	(4,132)	$ (5,497)
Accumulated Amortization	(13,439)	(12,482)
Intangible assets, net	10,635	10,227
In Process Research and Development [Member]
Gross Value	4,406
Accumulated Currency Translation Adjustment	(1,015)	(1,433)
Accumulated Amortization
Intangible assets, net	3,391	2,973
Developed Technology Rights [Member]
Gross Value	17,100
Accumulated Currency Translation Adjustment	(2,550)	(3,442)
Accumulated Amortization	(7,723)	(6,816)
Intangible assets, net	$ 6,827	6,842
Useful Life (Year)	15 years
Distribution Rights [Member]
Gross Value	$ 4,700
Accumulated Currency Translation Adjustment	(415)	(415)
Accumulated Amortization	(4,285)	(4,285)
Intangible assets, net
Useful Life (Year)	5 years
Patents [Member]
Gross Value	$ 1,000
Accumulated Currency Translation Adjustment	(152)	(207)
Accumulated Amortization	(431)	(381)
Intangible assets, net	$ 417	412
Useful Life (Year)	16 years
Elevess Trade Name [Member]
Gross Value	$ 1,000
Accumulated Currency Translation Adjustment
Accumulated Amortization	(1,000)	(1,000)
Intangible assets, net
Useful Life (Year)	9 years

Note 9 - Goodwill - Changes in

Note 9 - Goodwill - Changes in the Carrying Value of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance	$ 7,214	$ 7,482
Effect of foreign currency adjustments	1,004	(268)
Balance	$ 8,218	$ 7,214

Note 10 - Accrued Expenses - Su

Note 10 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Compensation and related expenses	$ 2,893	$ 3,089
Facility construction costs		804
Research grants	419	463
Clinical trial costs	2,318	227
Professional fees	448	802
Deferred rent		231
Other	248	880
Total	$ 6,326	$ 6,496

Note 11 - Commitments and Con53

Note 11 - Commitments and Contingencies (Details Textual) $ in Thousands	Oct. 09, 2015USD ($)ft²	Dec. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Operating Leases, Rent Expense		$ 1,800	$ 1,300	$ 1,300
Standard and Extended Product Warranty Accrual		0	$ 0
European Headquarters Facility [Member]
Area of Real Estate Property | ft²	33,000
Lessee Leasing Arrangements, Term of Contract	15 years
Lessee Leasing Arrangements, Number of Renewal Terms	3
Lessee Leasing Arrangements, Renewal Term	6 years
Lessee Leasing Arrangements Ability to Withdraw With Penalty	6 years
Lessee Leasing Arrangements Ability to Withdrawn Without Penalty	9 years
Lessee Leasing Arrangements Initial Yearly Rent	$ 300
Construction in Progress, Gross		3,100
European Headquarters Facility [Member] | Deposits and Other Assets, Noncurrent [Member]
Lessee Leasing Arrangements, Additional Tenant Improvements		$ 800
Abano Terme, Italy [Member]
Area of Real Estate Property | ft²		28,000

Note 11 - Commitments and Con54

Note 11 - Commitments and Contingencies - Future Lease Commitments (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 1,879
2,019	1,880
2,020	1,916
2,021	1,924
2,022	1,673
2023 and thereafter	1,311
Total	$ 10,583

Note 12 - Equity Incentive Pl55

Note 12 - Equity Incentive Plan (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jun. 18, 2013	Jun. 07, 2011	Jun. 05, 2009	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 13, 2017	Jun. 04, 2003
Allocated Share-based Compensation Expense				$ 5,807	$ 3,392	$ 2,225
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Appreciation Rights Vested and Expected to Vest Outstanding Weighted Average Exercise Price				$ 33.70
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Ppreciation Rights Vested and Expected to Vest Outstanding Aggregate Intrinsic Value				$ 27,600
Share-based Compensation Arrangement by Share-based Payment Award, Options and Stock Appreciation Rights, Outstanding, Weighted Average Remaining ContractualTerm				7 years
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Appreciation Rights Vested Aggregate Intrinsic Value				$ 22,000	16,700
Share-based Compensation Arrangement by Share-based Payment Award, Options and Stock Appreciation Rights, Outstanding, Intrinsic Value				27,600	22,300
Share-based Compensation Arrangement by Share-based Payment Award, Options and Stock Appreciation Rights, Exercises in Period, Total Intrinsic Value				500	2,100
Share-based Compensation Arrangement by Share-based Payment Award Options and Stock Appreciation Rights Vested in Period Fair Value				2,100	1,300
Proceeds from Stock Options Exercised				$ 314	$ 1,007	$ 1,074
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement Evaluation of Expected Volatility Assumption to Historical Volatility Average Period				4 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				67,567	87,158
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				9,970
Stock Options, SARs and Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				1,327,200
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized				$ 7,600
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 36 days
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 2,300	$ 1,000
Amended Two Thousand Three Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,800,000		2,350,000					1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	650,000		850,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs	1.5
Second Amended Two Thousand Three Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		3,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		800,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs		1.9
The 2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				1,100,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs							2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							1,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				85,109
The 2017 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				26,306
The 2017 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
The 2017 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
The 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				407,635
Two Thousand Three Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				64 years

Note 12 - Equity Incentive Pl56

Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Expected volatility
Expected life (years) (Year)	4 years	4 years 182 days	4 years 182 days
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate	1.60%	0.94%	1.15%
Expected volatility	38.74%	47.33%	53.15%
Maximum [Member]
Risk free interest rate	1.86%	1.55%	1.46%
Expected volatility	44.31%	51.61%	54.65%

Note 12 - Equity Incentive Pl57

Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation expense	$ 5,807	$ 3,392	$ 2,225
Cost of Sales [Member]
Stock-based compensation expense	439	148	42
Research and Development Expense [Member]
Stock-based compensation expense	564	467	269
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 4,804	$ 2,777	$ 1,914

Note 12 - Equity Incentive Pl58

Note 12 - Equity Incentive Plan - Stock Options and SAR's Activity (Details)	12 Months Ended
	Dec. 31, 2017$ / shares	Dec. 31, 2016$ / shares
Options and SAR's outstanding at beginning of year	979,569	762,260
Options and SAR's outstanding at beginning of year, Weighted Average Exercise Price Per Share (in dollars per share)	$ 26.15	$ 18.75
Options and SAR's Granted	440,688	354,275
Options and SAR's Granted, Weighted Average Exercise Price Per Share (in dollars per share)	$ 50.22	$ 40.77
Options and SAR's Cancelled	(74,527)	(58,841)
Options and SAR's Cancelled, Weighted Average Exercise Price Per Share (in dollars per share)	$ 45.56	$ 30.05
Options and SAR's Expired	(589)	(3,310)
Options and SAR's Expired, Weighted Average Exercise Price Per Share (in dollars per share)	$ 32.86	$ 11.37
Options and SAR's Exercised	(17,941)	(74,815)
Options and SAR's Exercised, Weighted Average Exercise Price Per Share (in dollars per share)	$ 20.56	$ 15.46
Options and SAR's outstanding at end of year	1,327,200	979,569
Options and SAR's outstanding at end of year, Weighted Average Exercise Price Per Share (in dollars per share)	$ 33.70	$ 26.15

Note 12 - Equity Incentive Pl59

Note 12 - Equity Incentive Plan - Summary of Exercisable Options and SAR's (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Incentive Stock Options [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	182,472
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 14.12
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	4 years 109 days
Non-qualified Stock Options [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	374,211
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 20.18
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	5 years 109 days
Performance Shares [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	32,598
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 38.79
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	7 years 255 days
Stock Appreciation Rights (SARs) [Member]
Exercisable Options and SAR's outstanding (in shares) | shares	35,250
Exercisable Options and SAR's, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 6.36
Exercisable Options and SAR's, Weighted Average Remaining Term (Year)	2 years 36 days

Note 12 - Equity Incentive Pl60

Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Unvested at Beginning of year (in shares)	207,077	150,384
Unvested at Beginning of year, weighted average grant date fair value (in dollars per share)	$ 36.44	$ 34.29
Granted (in shares)	67,567	87,158
Granted, weighted average grant date fair value (in dollars per share)	$ 52.03	$ 38.11
Cancelled (in shares)		(4,950)
Cancelled, weighted average grant date fair value (in dollars per share)		$ 36.20
Vested/Released (in shares)	(45,418)	(25,515)
Vested/Released, weighted average grant date fair value (in dollars per share)	$ 35.32	$ 33.35
Unvested at end of year (in shares)	229,226	207,077
Unvested at end of year, weighted average grant date fair value (in dollars per share)	$ 42.47	$ 36.44

Note 13 - Employee Benefit Pl61

Note 13 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	140.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	5.00%
Defined Contribution Plan, Employer Matching Contribution, Amount	$ 0.6	$ 0.6	$ 0.4

Note 14 - Shareholder Rights 62

Note 14 - Shareholder Rights Plan (Details Textual) - Shareholder Rights Plan Two Thousand Eight [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Apr. 04, 2008
Exercise Price per Share	$ 75
Stock Redemption Price per Share	0.01
Series B Junior Participating Preferred Stock [Member]
Stock Redemption Price per Share	$ 0.01
Preferred Stock, Capital Shares Reserved for Future Issuance	175,000
Minimum [Member]
Stock Holders Rights Plan Exercisability Threshold Percentage		15.00%
Maximum [Member]
Stockholder Rights Plan Exercise Trigger Threshold Percentage Voting Stock Ownership Offer		15.00%
Percentage of Beneficial Ownership Interests	50.00%

Note 15 - Revenue by Product 63

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2011	Dec. 31, 2003	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012
Concentration Risk, Percentage			100.00%	100.00%	100.00%
Sales Revenue, Services, Net			$ 5,637,000	$ 447,000	$ 5,303,000
Mitek ORTHOVISC Agreement [Member]
License Agreement Term		10 years
License Agreement Additional Term			5 years			5 years
Mitek MONOVISC Agreement [Member]
License Agreement Term	15 years
Revenue Recognition, Milestone Method, Revenue Recognized			$ 5,000,000	$ 0	5,000,000
Revenue Recognition, Milestone Method, Revenue Milestone in Twelve Month Period			$ 100,000,000		$ 50,000,000
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | DePuy Mitek Inc [Member]
Concentration Risk, Percentage			73.00%	75.00%	72.00%

Note 15 - Revenue by Product 64

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic Information - Product Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Product Revenue	$ 28,884	$ 27,178	$ 28,340	$ 23,381	$ 28,296	$ 25,783	$ 26,575	$ 22,278	$ 107,783	$ 102,932	$ 87,696
Concentration risk, percentage									100.00%	100.00%	100.00%
Orthobiologics [Member]
Product Revenue									$ 93,816	$ 89,695	$ 73,247
Concentration risk, percentage									87.00%	87.00%	84.00%
Dermal [Member]
Product Revenue									$ 2,755	$ 2,759	$ 2,266
Concentration risk, percentage									3.00%	3.00%	2.00%
Surgical [Member]
Product Revenue									$ 5,262	$ 5,427	$ 5,812
Concentration risk, percentage									5.00%	5.00%	7.00%
Other [Member]
Product Revenue									$ 5,950	$ 5,051	$ 6,371
Concentration risk, percentage									5.00%	5.00%	7.00%

Note 15 - Revenue by Product, b

Note 15 - Revenue by Product, by Significant Customer and by Geographic Region; Geographic Information - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total Revenue	$ 29,388	$ 27,184	$ 33,462	$ 23,386	$ 28,726	$ 25,789	$ 26,581	$ 22,283	$ 113,420	$ 103,379	$ 92,999
Percentage of Revenue									100.00%	100.00%	100.00%
UNITED STATES
Total Revenue									$ 92,905	$ 83,972	$ 76,621
Percentage of Revenue									82.00%	81.00%	82.00%
Europe [Member]
Total Revenue									$ 12,435	$ 10,953	$ 8,756
Percentage of Revenue									11.00%	11.00%	9.00%
Other Location [Member]
Total Revenue									$ 8,080	$ 8,454	$ 7,622
Percentage of Revenue									7.00%	8.00%	9.00%

Note 15 - Revenue by Product 66

Note 15 - Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, net	$ 56,183	$ 52,296
UNITED STATES
Property and equipment, net	52,828	49,140
ITALY
Property and equipment, net	$ 3,355	$ 3,156

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%		35.00%	35.00%	35.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ (2,300)
Operating Loss Carryforwards			$ 4,000
Unrecognized Tax Benefits			0	$ 0
Income Tax Expense (Benefit)			14,386	18,323	$ 17,496
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation				$ 647	$ 847
Accounting Standards Update 2016-09 [Member]
Income Tax Expense (Benefit)			$ (400)
Domestic Tax Authority [Member] | Earliest Tax Year [Member]
Open Tax Year			2,014
Domestic Tax Authority [Member] | Latest Tax Year [Member]
Open Tax Year			2,016
Foreign Tax Authority [Member] | Earliest Tax Year [Member]
Open Tax Year			2,011
Foreign Tax Authority [Member] | Latest Tax Year [Member]
Open Tax Year			2,016
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 16 - Income Taxes - Compon

Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Domestic	$ 48,446	$ 50,181	$ 48,608
Foreign	(2,244)	689	(354)
Income before income taxes	46,202	50,870	48,254
Current provision:
Federal	12,608	14,982	14,572
State	2,737	3,265	3,635
Foreign	31	302	249
	15,376	18,549	18,456
Deferred provision:
Federal	(426)	(70)	(370)
State	(68)	(84)	(33)
Foreign	(496)	(72)	(557)
	(990)	(226)	(960)
Total provision	$ 14,386	$ 18,323	$ 17,496

Note 16 - Income Taxes - Signif

Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Net operating loss carry forward, foreign	$ 959	$ 1,253
Stock-based compensation expense	2,309	1,882
Foreign currency exchange	265	677
Accrued expenses and other	496	308
Inventory reserve	740	640
Deferred tax assets	4,769	4,760
Acquisition-related Intangibles	(2,743)	(2,932)
Depreciation	(7,419)	(8,376)
Deferred tax liabilities	(10,162)	(11,308)
Net deferred tax liabilities	$ (5,393)	$ (6,548)

Note 16 - Income Taxes - Reconc

Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statutory federal income tax rate	35.00%	35.00%	35.00%	35.00%
State tax expense, net of federal benefit		4.80%	4.50%	4.80%
Impact of rate change on deferred taxes		(4.90%)	0.00%	0.00%
Permanent items, including nondeductible expenses		0.60%	0.50%	(0.30%)
State investment tax credit		(0.70%)	(0.10%)	0.00%
Federal, state and foreign research and development credits		(1.40%)	(0.90%)	(0.40%)
Foreign rate differential		0.50%	(0.10%)	0.10%
Domestic production deduction		(2.80%)	(2.90%)	(2.90%)
Effective income tax rate		31.10%	36.00%	36.30%

Note 17 - Revolving Credit Ag71

Note 17 - Revolving Credit Agreement (Details Textual) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Oct. 24, 2017	Dec. 31, 2017
Debt Instrument, Term	5 years
Line of Credit Facility, Current Borrowing Capacity	$ 50,000
Line of Credit Facility, Additional Borrowing Capacity	50,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000
Line of Credit Facility, Commitment Fee Percentage	0.25%
Long-term Line of Credit		$ 0
Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Federal Funds Effective Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%

Note 18 - Quarterly Financial72

Note 18 - Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Product revenue	$ 28,884	$ 27,178	$ 28,340	$ 23,381	$ 28,296	$ 25,783	$ 26,575	$ 22,278	$ 107,783	$ 102,932	$ 87,696
Total revenue	29,388	27,184	33,462	23,386	28,726	25,789	26,581	22,283	113,420	103,379	92,999
Cost of product revenue	8,716	6,250	6,315	6,083	7,539	4,998	6,065	5,425	27,364	24,027	21,053
Gross profit on product revenue	20,168	20,928	22,025	17,298	20,757	20,785	20,510	16,853
Net income	$ 8,067	$ 6,887	$ 11,369	$ 5,493	$ 8,085	$ 8,952	$ 8,615	$ 6,895	$ 31,816	$ 32,547	$ 30,758
Net income (in dollars per share)	$ 0.55	$ 0.47	$ 0.78	$ 0.38	$ 0.56	$ 0.61	$ 0.59	$ 0.46	$ 2.18	$ 2.22	$ 2.06
Basic common shares outstanding (in shares)	14,596	14,579	14,588	14,576	14,538	14,625	14,679	14,875
Diluted net income per share (in dollars per share)	$ 0.53	$ 0.46	$ 0.76	$ 0.37	$ 0.54	$ 0.59	$ 0.57	$ 0.45	$ 2.11	$ 2.15	$ 2.01
Diluted common shares outstanding (in shares)	15,141	15,115	15,044	15,043	14,979	15,077	15,111	15,307	15,068	15,116	15,321